Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Background More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year. Because these tumors are so rare, there are few proven therapies. This study will test whether the immunotherapy drug nivolumab is an effective …

renal function
cortisone
gliosarcoma
meningioma
ependymoma
  • 120 views
  • 05 Apr, 2021
  • 1 location
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this phase 1 trial is to determine the maximum tolerated dose (MTD), food effect, safety and tolerability of oral ONC206 in patients with recurrent, primary CNS neoplasms.

oligodendroglioma, anaplastic
astrocytoma, anaplastic
gliosarcoma
ependymoma
MRI
  • 0 views
  • 23 Apr, 2021
  • 1 location
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

The purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with Pembrolizumab. LITT is a minimally invasive surgical technique that uses a laser to heat brain tumors. Pembrolizumab is an investigational (experimental) drug that works by helping participants' immune system …

  • 15 views
  • 16 May, 2021
  • 2 locations
Rare CNS Tumors Outcomes &Risk

sarcoma (Gliosarcoma). Design: (Registered Trademark)Participants will be invited to participate through an ad on the CERN Foundation website (ependymoma), information on the Neuro-Oncology Branch

oligodendroglioma, anaplastic
primitive neuroectodermal tumor
medulloblastoma
cancer
anaplastic oligodendroglioma
  • 22 views
  • 31 May, 2021
  • 1 location
Ex Vivo Drug Sensitivity Testing and Mutation Profiling

This study is a prospective, non-randomized feasibility study. Freshly isolated tumor cells from patients will be screened using state-of-the-art viability assay designed for ex vivo high-throughput drug sensitivity testing (DST). In addition, genetic information will be obtained from cancer and normal (germline) tissue and correlated with drug response. This study …

tumor cells
hematologic malignancy
cancer
  • 61 views
  • 24 Jan, 2021
  • 1 location